Systematic benchmarking of large Language models in programmed cell death-oriented gastric cancer research: a comparative analysis of DeepSeek‑V3, DeepSeek‑R1, and Claude 3.5

在以程序性细胞死亡为导向的胃癌研究中,对大型语言模型进行系统性基准测试:DeepSeek-V3、DeepSeek-R1 和 Claude 3.5 的比较分析

阅读:1

Abstract

OBJECTIVES: We intended to compare three language models (DeepSeek‑V3, DeepSeek‑R1, and Claude 3.5) regarding their ability to address programmed cell death mechanisms in gastric cancer. We aimed to establish which model most accurately reflects clinical standards and guidelines. METHODS: Fifty-five frequently posed questions and twenty guideline-oriented queries on cell death processes were collected from recognized gastroenterology and oncology resources. Each model received every question individually. Six independent specialists, each from a distinct hospital, rated responses from 1 to 10, and their scores were summed to a 60-point total. Answers achieving totals above 45 were classified as "good," 30 to 45 as "moderate," and below 30 as "poor." Models that delivered "poor" replies received additional prompts for self‑correction, and revised answers underwent the same review. RESULTS: DeepSeek‑R1 showed higher total scores than the other two models in almost every topic, particularly for surgical protocols and multimodal therapies. Claude 3.5 ranked second, displaying mostly coherent coverage but occasionally omitting recent guideline updates. DeepSeek‑V3 had difficulty with intricate guideline-based material. In "poor" responses, DeepSeek‑R1 corrected errors markedly, shifting to a "good" rating upon re-evaluation, while DeepSeek‑V3 improved only marginally. Claude 3.5 consistently moved its "poor" answers up into the moderate range. CONCLUSION: DeepSeek‑R1 demonstrated the strongest performance for clinical content linked to programmed cell death in gastric cancer, while Claude 3.5 performed moderately well. DeepSeek‑V3 proved adequate for more basic queries but lacked sufficient detail for advanced guideline-based scenarios. These findings highlight the potential and limitations of such automated models when applied in complex oncologic contexts.

特别声明

1、本页面内容包含部分的内容是基于公开信息的合理引用;引用内容仅为补充信息,不代表本站立场。

2、若认为本页面引用内容涉及侵权,请及时与本站联系,我们将第一时间处理。

3、其他媒体/个人如需使用本页面原创内容,需注明“来源:[生知库]”并获得授权;使用引用内容的,需自行联系原作者获得许可。

4、投稿及合作请联系:info@biocloudy.com。